Abstract 34P
Background
Small cell lung cancer (SCLC) is a highly aggressive tumor with early primary resistance and modest clinical response to immune checkpoint blockade (ICB). Mutations or transcriptional repression of the major histocompatibility complex class I (MHC-I) represent a key mechanism driving resistance to T cell-based therapies. Lysine-specific demethylase 1 (LSD1) regulates gene expression via demethylating lysines 4 and 9 of histone H3 and has been regarded as a promising therapeutic target in SCLC. Here we investigated the immunomodulatory functions of LSD1 in regulating MHC-I antigen presentation pathway (APP) and resistance to immunotherapy in SCLC.
Methods
To perturb LSD1 function, we employed the pharmacological inhibitor ORY-1001 and RNA interference to assess changes in MHC-I expression in SCLC cell lines by flow cytometry and western blot. We then performed RNA-seq to characterize whole transcriptomic changes in SCLC cells following LSD1 inhibition. To explore effects of targeting LSD1 on T cell cytolysis, we co-cultured SCLC presenting endogenous peptides with pre-activated primary cognate CD8+ T cells. Finally, we treated syngeneic immunocompetent mice bearing genetically engineered mouse model (GEMM)-derived tumors with ORY1001 and/or anti-PD-L1 to evaluate tumor growth and characterize intratumor immune activities.
Results
We discovered a significant and strong negative correlation between expressions of KDM1A and MHC-I/APP genes in SCLC cell lines. We then demonstrated that targeting LSD1 restores MHC-I cell surface expression, transcriptionally activates APP-regulatory genes, and enhances the immunogenic profile of SCLC. Perturbation of LSD1 activates interferon signaling, specifically activating a transactivator of MHC-I genes, and functionally rescues MHC-I-restricted T cell recognition and cytolysis. Concurrent treatment of LSD1 inhibitor and anti-PD-L1 sensitizes refractory SCLC models to ICB via antitumor CD8 T cell activities.
Conclusions
Our data define LSD1 as a potent regulator of antigen presentation in the tumor and provide translational support for combinatory use of LSD1 inhibitors to enhance ICB sensitivity in SCLC and other MHC-I-deficient tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Sen: Financial Interests, Personal, Research Grant: Jazz Therapeutics. C.M. Rudin: Financial Interests, Personal, Advisory Board: Bridge Medicines, Earli, Harpoon Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
24P - Fibroblast growth factor receptor (FGFR) as a target for epigenetic therapies: A case review for a new approach to target tumors with somatic mutations/amplifications of FGFR
Presenter: M. Nezami
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Relationship between aberrant methylation of CpG islands of microRNA gene promoters and changes in their expression in epithelial ovarian cancer
Presenter: Irina Pronina
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - 3MST: A potential workhorse in H2S signaling trimmed by microRNA-548 in breast cancer
Presenter: Alyaa Dawoud
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
Presenter: Yun Fan
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Deep learning approach for discovering new predictive histological features of immunotherapy response
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma
Presenter: Jinpeng Li
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Nomogram to predict survival of patients with unresectable melanoma receiving immune checkpoint inhibitors
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Therapeutic vaccination with HPV-16 oncoproteins fused into a checkpoint modifier of early T cell activation protects against HPV-associated tumors in a preclinical model
Presenter: Susan Currie
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?
Presenter: Zhulin Yin
Session: Cocktail & Poster Display session
Resources:
Abstract
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract